Axillary Hyperhidrosis - Pipeline Insight, 2024

Axillary Hyperhidrosis - Pipeline Insight, 2024

DelveInsight’s, “Axillary Hyperhidrosis- Pipeline Insight, 2024” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Axillary Hyperhidrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Axillary Hyperhidrosis: Understanding

Axillary Hyperhidrosis: Overview

Hyperhydrosis is a medical condition that causes excessive sweating. The word “hyperhidrosis” (hi-purr-hi-DROE-sis) means too much (hyper) sweating (hidrosis). Primary hyperhidrosis is a rare disorder characterized by excessive sweating on the palms of the hands, the soles of the feet, in the armpits (axillary), in the groin area, and/or under the breasts. Etiology of axillary hyperhidrosis is unknown but is related to increased cholinergic sympathetic stimulation of the sweat glands in the axilla. Although the glands invariably become remarkably hypertrophied in this condition, the dramatic glandular growth and oversecretion is believed to be secondary rather than primary The symptoms of primary hyperhidrosis typically begin during childhood or puberty and may often, although not always, persist throughout a person’s life. Affected individuals may experience a heightened reaction to certain stimuli that can cause sweating such as anxiety, pain, exercise, tension, caffeine, and/or nicotine. Extreme sweating may occasionally occur all over the body (generalized) or it may be localized in the palms of the hands and the soles of the feet (palmar-plantar hyperhidrosis); the underarm area (axilla); the groin; and under the breasts. The face may be affected in the form of persistent blushing accompanying the excessive sweating. When the palms and soles are involved, the skin may develop an abnormal pink or bluish-white appearance. The skin may also become unusually soft (macerated), cracked, or scaly, particularly on the feet. Many factors can contribute to axillary hyperhidrosis including genetic influences as well as physical and emotional stress. A family history is present in up to 30% of cases. It may be mild with occasional sweaty patches or severe with constant sweating throughout the waking hours of the day.

“Axillary Hyperhidrosis- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Axillary Hyperhidrosis pipeline landscape is provided which includes the disease overview and Axillary Hyperhidrosis treatment guidelines. The assessment part of the report embraces, in depth Axillary Hyperhidrosis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Axillary Hyperhidrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Axillary Hyperhidrosis R&D. The therapies under development are focused on novel approaches to treat/improve Axillary Hyperhidrosis.

Axillary Hyperhidrosis Emerging Drugs Chapters

This segment of the Axillary Hyperhidrosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Axillary Hyperhidrosis Emerging Drugs

• Sofpironium bromide: Brickell Biotech Inc.

Sofpironium bromide is a new chemical entity that we are currently developing in the U.S. as a potential best-in-class, self-administered, once-daily, topical therapy for the treatment of primary axillary hyperhidrosis, or excessive underarm sweating. The drug is a retro metabolically designed anticholinergic agent which selectively binds to M3 AC receptor potentially inhibiting sweat production.

• ET-01: Eirion Therapeutics

ET-01 is a topical botulinum product being developed with the goal of avoiding the pain, bleeding and bruising that can be associated with the injection of commercially available botulinum products. ET-01 employs a nanoemulsion transdermal delivery technology essential for a large molecule such as botulinum to penetrate into the skin.The drug is currently being developed in Phase 2 stage of development for the treatment of Axillary Hyperhidrosis.

• DMT410: Dermata Therapeutics LLC pipeline

DMT410 is the second development program using DMT400 combination regimen in combination with botulinum toxin. Dermata Therapeutics have completed a proof of concept, Phase 1 clinical trial using DMT410 in combination with BOTOX® for the treatment of primary axillary hyperhidrosis. The treatment was well tolerated, and a majority of patients saw a reduction in sweat production similar to results seen from using injections of BOTOX®.

Further product details are provided in the report……..

Axillary Hyperhidrosis: Therapeutic Assessment

This segment of the report provides insights about the different Axillary Hyperhidrosis drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Axillary Hyperhidrosis

There are approx. 3+ key companies which are developing the therapies for Axillary Hyperhidrosis. The companies which have their Axillary Hyperhidrosis drug candidates in the most advanced stage, i.e. phase III include, Brickell Biotech Inc.

• Phases

DelveInsight’s report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Axillary Hyperhidrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
• Molecule Type

Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Axillary Hyperhidrosis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Axillary Hyperhidrosis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Axillary Hyperhidrosis drugs.

Axillary Hyperhidrosis Report Insights

• Axillary Hyperhidrosis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Axillary Hyperhidrosis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Axillary Hyperhidrosis drugs?
• How many Axillary Hyperhidrosis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diffuse Large B-Cell Lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Axillary Hyperhidrosis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Axillary Hyperhidrosis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Brickell Biotech Inc.
• Dermata Therapeutics LLC
• Eirion Therapeutics
• Theravida
• GlaxoSmithKline
• Medytox

Key Products

• Sofpironium bromide
• ET-01
• DMT410
• Umeclidinium